Computed aided classification of circulating tumor cell and CK+ subclasses.

2012 ◽  
Vol 30 (30_suppl) ◽  
pp. 54-54
Author(s):  
Oleg Gusyatin ◽  
David Tims ◽  
Aladin Milutinovic ◽  
Chunsheng Jiang

54 Background: Fluorescence microscopy imaging system (OnQView, On-Q-ity, Waltham, MA) in combination with advanced cell capture techniques (OnQChip, On-Q-ity, Waltham, MA) provides necessary sensitivity to detect circulating tumor cells (CTCs) in a blood sample. The detection process involves automatic identification of CTC candidates from the collected imagery followed by CTC subclass identification. Subclass identification process is manual and usually leads to increased sample processing time. Methods: We have developed a fully automated CTC detection and classification system allowing for substantial increase in throughput while maintaining high sensitivity and specificity. Detection is accomplished by a robust segmentation technique. A set of 25 image-based features is automatically computed for each detected candidate. Features include texture measurements, morphology measurements, multichannel intensity and contextual characteristics. All CTC subclasses as well as artifact classes are manually labeled and verified by trained imaging technologists.A hierarchy of Multi-Layer Perceptron Neural Network (MLPNN) classifiers is then trained and used to identify and reject artifacts and to identify CTC subclasses. Results: A total of 27 prostate cancer patients and 33 normal controls with two 3.75ml blood samples per patient were used to validate techniques. Probability of successful artifact rejection was achieved to be 0.78 and probabilities of subsequent successful CTC subclass identification ranged between 0.79 and 0.98 (intact CTCs = 95%; irregular CTCs = 98%; fragmented CTCs = 82%). Conclusions: A fully automated CTC detection and classification system was developed. Testing was conducted with 27 prostate cancer patients and 33 normal controls to yield an artifact rejection probability of 0.78 and CTC subclass identification probabilities of 0.79 to 0.98.

1986 ◽  
Vol 1 (2) ◽  
pp. 67-76 ◽  
Author(s):  
Manabu Kuriyama

Prostate-specific antigen (PA) has been evaluated clinically as a tumor marker of prostate cancer with the use of enzyme immunoassay (EIA). For serodetection of prostate cancer, PA was assayed in a total of 1,109 sera. From mean ± 3 S.D. of normal controls, upper cut-off values in males were decided as 2.5 and 1.2 ng/ml in Americans and Japanese, respectively. Serum PA values in prostate cancer patients were positive in 78% of Americans and 62% of Japanese. However, in benign prostatic hypertrophy (BPH) cases, a high false positive rate of 41% was observed in Americans. Simultaneous assays of serum PA and PAP showed high sensitivity and specificity in the detection of prostate cancer. This antigen could be used, as well as PAP, for monitoring prostate cancer patients. Furthermore, serum PA levels prior to treatment may express to some degree the malignant potential of the cancer. These results suggest that PA may be useful as a tumor marker of prostate cancer.


2012 ◽  
Vol 30 (30_suppl) ◽  
pp. 41-41
Author(s):  
Matthew M. Cooney ◽  
Cheryl L. Thompson ◽  
Po-Yuan Lin ◽  
Kai-Lun Cheng ◽  
James D. McGuffin-Cawley ◽  
...  

41 Background: A promising prostate cancer biomarker, alpha-methylacyl-CoA racemase (AMACR), has demonstrated the ability to distinguish cancer from healthy and benign cells with high sensitivity and specificity. However the lack of a good clinical assay has limited its translation into the clinic. Here we report on the development of a single use disposable biosensor for AMACR detection. Methods: This is a very inexpensive, small, single-use disposable sensor that requires only a drop of plasma and connects to a portable device. The biosensor utilizes the reaction of pristanic acid with a substrate that includes AMACR to produce Trans-2,3-dehydropritanayl-CoA plus H2O2. The biosensor utilizes iridium oxide nanoparticle catalyst to oxidize the H2O2 produced in the above metabolic pathway. Thus the oxidation of H2O2 yields a measurable current to quantify AMACR in the sample. This is the first in vitro assay method for AMACR based on this reaction mechanism. Results: In our study including plasma from 9 healthy males, 10 patients with high grade prostatic intraepithelial neoplasia and 5 prostate cancer patients we show 100% accuracy in separating prostate cancer patients from controls as well as those with benign prostate conditions. Conclusions: Our data provides strong evidence for the ability of this biosensor to perform as a reliable assay for prostate cancer detection and diagnosis.


2007 ◽  
Vol 177 (4S) ◽  
pp. 130-130
Author(s):  
Markus Graefen ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Felix K.-H. Chun ◽  
Alwyn M. Reuther ◽  
...  

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document